Hold for GOLD28 Feb 2021 09:17
MGC Pharma's research program into the use of cannabinoids in the treatment of aggressive glioblastoma brain cancer has been expanded, in collaboration with the Slovenian National Institute of Biology and Neurosurgery Department at the University Medical Centre
· Preliminary results of MGC Pharma's proprietary cannabinoid treatment of Glioblastoma have recently completed an independent peer review and been formally published in the MDPI (Multidisciplinary Digital Publishing Institute) Medical Journal
· The new, expanded study will also explore the use of a nanoparticle delivery system to improve the effects of the glioblastoma
h